药品注册申请号:076575
申请类型:ANDA (仿制药申请)
申请人:TEVA
申请人全名:TEVA PHARMACEUTICALS USA INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG No No AB 2009/04/17 2009/04/17 Prescription
002 TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG No No AB 2009/04/17 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/01/09 SUPPL-22(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-21(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-20(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-18(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-16(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-15(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-14(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-13(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-12(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-10(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-9(补充) Approval Labeling STANDARD
2024/01/09 SUPPL-8(补充) Approval Labeling STANDARD
2014/11/18 SUPPL-7(补充) Approval Labeling STANDARD
2014/11/18 SUPPL-6(补充) Approval Labeling STANDARD
2014/11/18 SUPPL-5(补充) Approval Labeling STANDARD
2014/11/18 SUPPL-4(补充) Approval Labeling STANDARD
2011/07/14 SUPPL-3(补充) Approval Labeling
2010/10/30 SUPPL-2(补充) Approval Labeling
2009/09/30 SUPPL-1(补充) Approval Labeling
2009/04/17 ORIG-1(原始申请) Approval
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:TOPIRAMATE 剂型/给药途径:CAPSULE;ORAL 规格:15MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020844 001 NDA TOPAMAX TOPIRAMATE CAPSULE;ORAL 15MG Prescription Yes No AB 1998/10/26 JANSSEN PHARMS
076575 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2009/04/17 TEVA
078418 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2009/10/14 STRIDES PHARMA
078877 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2009/10/14 ZYDUS PHARMS USA INC
215449 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2023/09/27 AUROBINDO PHARMA LTD
217694 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2023/12/05 TWI PHARMS
218482 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2024/06/13 ALKEM LABS LTD
217869 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2024/07/16 GLENMARK PHARMS LTD
218642 001 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 15MG Prescription No No AB 2024/10/10 SENORES PHARMS
活性成分:TOPIRAMATE 剂型/给药途径:CAPSULE;ORAL 规格:25MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020844 002 NDA TOPAMAX TOPIRAMATE CAPSULE;ORAL 25MG Prescription Yes Yes AB 1998/10/26 JANSSEN PHARMS
076575 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2009/04/17 TEVA
078418 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2009/10/14 STRIDES PHARMA
078877 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2009/10/14 ZYDUS PHARMS USA INC
215449 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2023/09/27 AUROBINDO PHARMA LTD
217694 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2023/12/05 TWI PHARMS
218482 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2024/06/13 ALKEM LABS LTD
217869 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2024/07/16 GLENMARK PHARMS LTD
218642 002 ANDA TOPIRAMATE TOPIRAMATE CAPSULE;ORAL 25MG Prescription No No AB 2024/10/10 SENORES PHARMS
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database